A Response to: Letter to the Editor Regarding 'Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults'

MLA

Mihaela Georgieva, et al. “A Response to: Letter to the Editor Regarding ‘Real-World Effectiveness of a Third Dose of MRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.’” Infectious Diseases and Therapy, vol. 13, no. 11, Sept. 2024, pp. 2457–59. EBSCOhost, https://doi.org/10.1007/s40121-024-01039-5.

APA

Mihaela Georgieva, Tianyu Sun, & Ekkehard Beck. (2024). A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.” Infectious Diseases and Therapy, 13(11), 2457–2459. https://doi.org/10.1007/s40121-024-01039-5

Chicago

Mihaela Georgieva, Tianyu Sun, and Ekkehard Beck. 2024. “A Response to: Letter to the Editor Regarding ‘Real-World Effectiveness of a Third Dose of MRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.’” Infectious Diseases and Therapy 13 (11): 2457–59. doi:10.1007/s40121-024-01039-5.